JP2024509920A5 - - Google Patents
Info
- Publication number
- JP2024509920A5 JP2024509920A5 JP2023555245A JP2023555245A JP2024509920A5 JP 2024509920 A5 JP2024509920 A5 JP 2024509920A5 JP 2023555245 A JP2023555245 A JP 2023555245A JP 2023555245 A JP2023555245 A JP 2023555245A JP 2024509920 A5 JP2024509920 A5 JP 2024509920A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- cancer
- formulation according
- seq
- bispecific anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158552P | 2021-03-09 | 2021-03-09 | |
| US63/158,552 | 2021-03-09 | ||
| PCT/IB2022/052009 WO2022189942A1 (en) | 2021-03-09 | 2022-03-07 | Treatment of cancers lacking egfr-activating mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024509920A JP2024509920A (ja) | 2024-03-05 |
| JP2024509920A5 true JP2024509920A5 (cg-RX-API-DMAC10.html) | 2025-03-13 |
Family
ID=80738936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555245A Pending JP2024509920A (ja) | 2021-03-09 | 2022-03-07 | Ｅｇｆｒ活性化変異を欠くがんの治療 |
Country Status (13)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4204455A4 (en) | 2020-08-25 | 2024-10-16 | Janssen Biotech, Inc. | Treatment of non-small cell lung cancer with egfr mutations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| AU2005250484B2 (en) | 2004-06-04 | 2011-08-11 | Genentech, Inc. | EGFR mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| KR102373193B1 (ko) * | 2012-11-21 | 2022-03-10 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| WO2014148557A1 (ja) * | 2013-03-19 | 2014-09-25 | 凸版印刷株式会社 | Ｅｇｆｒ阻害剤感受性予測方法 |
| BR112019010020A2 (pt) | 2016-11-17 | 2019-08-20 | Univ Texas | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 |
| MX2021010265A (es) * | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
-
2022
- 2022-03-07 IL IL305700A patent/IL305700A/en unknown
- 2022-03-07 EP EP22710172.2A patent/EP4304644A1/en not_active Withdrawn
- 2022-03-07 AU AU2022233518A patent/AU2022233518A1/en not_active Abandoned
- 2022-03-07 CA CA3212669A patent/CA3212669A1/en active Pending
- 2022-03-07 JP JP2023555245A patent/JP2024509920A/ja active Pending
- 2022-03-07 BR BR112023018278A patent/BR112023018278A2/pt unknown
- 2022-03-07 MX MX2023010633A patent/MX2023010633A/es unknown
- 2022-03-07 WO PCT/IB2022/052009 patent/WO2022189942A1/en not_active Ceased
- 2022-03-07 CN CN202280019912.6A patent/CN116997358A/zh active Pending
- 2022-03-07 US US17/687,984 patent/US20220298248A1/en not_active Abandoned
- 2022-03-07 KR KR1020237034184A patent/KR20230156094A/ko active Pending
-
2023
- 2023-09-06 CL CL2023002663A patent/CL2023002663A1/es unknown
- 2023-09-07 JO JOJO/P/2023/0211A patent/JOP20230211A1/ar unknown
-
2024
- 2024-04-17 CL CL2024001201A patent/CL2024001201A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024153659A5 (cg-RX-API-DMAC10.html) | ||
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| JP2024161445A (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| CN103533961B (zh) | 以表皮生长因子受体为靶向的治疗癌症的组合方法 | |
| JP2022521610A5 (cg-RX-API-DMAC10.html) | ||
| JP2025501175A (ja) | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ | |
| JP2023513297A5 (cg-RX-API-DMAC10.html) | ||
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| JP7783182B2 (ja) | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 | |
| JP2023539589A5 (cg-RX-API-DMAC10.html) | ||
| JP2026021442A (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物 | |
| JP2022533211A (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| CN118401259A (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| TW202535477A (zh) | 抗ｂ７ｈ３抗體—藥物偶聯物治療癌症的方法 | |
| JP2022531980A5 (cg-RX-API-DMAC10.html) | ||
| TW202329936A (zh) | 抗體-藥物結合物與parp1選擇性抑制劑之組合 | |
| WO2025162287A1 (zh) | 抗her2抗体药物偶联物治疗肠癌的用途 | |
| US20220298248A1 (en) | Treatment of Cancers Lacking EGFR- Activating Mutations | |
| CN116265030A (zh) | 包含酪氨酸激酶抑制剂德立替尼的药物组合 | |
| WO2023072043A1 (zh) | 治疗肿瘤的联用药物 | |
| Van Cutsem | Optimizing Administration of Epidermal Growth Factor Receptor–Targeted Agents in the Treatment of Colorectal Cancer | |
| EA050641B1 (ru) | Лечение раковых заболеваний без активирующих мутаций egfr | |
| HK40102929A (en) | Treatment of cancers lacking egfr-activating mutations | |
| WO2025087386A1 (zh) | 抗her2抗体药物偶联物治疗乳腺癌的用途 |